Arvinas
Biotechnology company focused on discovery and development of targeted protein degraders (PROTACs) for oncology and neurology. Maintains an integrated discovery engine combining medicinal chemistry, structural biology, proteomics, AI/ML, and preclinical/clinical development. Has advanced multiple oral and brain-penetrant degraders into clinical trials and contributed to the first FDA approval of a PROTAC therapy.
Industries
Nr. of Employees
large (251-1000)
Patents
Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US-12036209-B2
View DetailsCompounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US-11065231-B2
View Details
Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US-12036209-B2
View DetailsCompounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US-11065231-B2
View DetailsProducts
VEPPANU (vepdegestrant)
An orally administered estrogen receptor degrader approved in the U.S. for a specified advanced or metastatic ER+/HER2- breast cancer population, developed using targeted protein degradation approaches.
ARV-102 (LRRK2 degrader)
Investigational orally bioavailable, brain-penetrant PROTAC designed to degrade LRRK2 for neurodegenerative diseases; evaluated in Phase 1/1b studies for Parkinson’s disease and related indications.
ARV-027 (polyQ-AR degrader)
Investigational oral, peripherally restricted PROTAC intended to selectively degrade polyglutamine-expanded androgen receptor in skeletal muscle for spinal-bulbar muscular atrophy; evaluated in Phase 1/1b studies.
ARV-393 (BCL6 degrader)
Investigational orally bioavailable PROTAC designed to degrade BCL6 for B-cell lymphomas; evaluated as monotherapy and in combination in Phase 1 trials.
ARV-6723 (HPK1 degrader)
Investigational oral PROTAC targeting HPK1 to modulate immune signaling in solid tumors; evaluated in Phase 1/2 studies as monotherapy and in combination with immune checkpoint inhibitors.
ARV-806 (KRAS G12D degrader)
Investigational PROTAC designed to selectively degrade mutant KRAS G12D in solid tumors; evaluated in Phase 1/2 dose-escalation clinical trial.
VEPPANU (vepdegestrant)
An orally administered estrogen receptor degrader approved in the U.S. for a specified advanced or metastatic ER+/HER2- breast cancer population, developed using targeted protein degradation approaches.
ARV-102 (LRRK2 degrader)
Investigational orally bioavailable, brain-penetrant PROTAC designed to degrade LRRK2 for neurodegenerative diseases; evaluated in Phase 1/1b studies for Parkinson’s disease and related indications.
ARV-027 (polyQ-AR degrader)
Investigational oral, peripherally restricted PROTAC intended to selectively degrade polyglutamine-expanded androgen receptor in skeletal muscle for spinal-bulbar muscular atrophy; evaluated in Phase 1/1b studies.
ARV-393 (BCL6 degrader)
Investigational orally bioavailable PROTAC designed to degrade BCL6 for B-cell lymphomas; evaluated as monotherapy and in combination in Phase 1 trials.
ARV-6723 (HPK1 degrader)
Investigational oral PROTAC targeting HPK1 to modulate immune signaling in solid tumors; evaluated in Phase 1/2 studies as monotherapy and in combination with immune checkpoint inhibitors.
ARV-806 (KRAS G12D degrader)
Investigational PROTAC designed to selectively degrade mutant KRAS G12D in solid tumors; evaluated in Phase 1/2 dose-escalation clinical trial.
Expertise Areas
- Targeted protein degradation drug discovery
- Medicinal chemistry for oral and CNS-penetrant small molecules
- Structural biology and computational modeling
- Proteomics-driven selectivity assessment
Key Technologies
- PROTAC targeted protein degradation
- DNA-encoded library (DEL) screening
- Structural modeling of ternary complexes
- AI/ML multiparametric predictive models
News & Updates
A research award recognizing innovation in targeted protein degradation with a $25,000 monetary prize; applications open Nov 1, 2026 and close Dec 31, 2026.
Peer-reviewed publication reporting Phase I/II clinical data for a PROTAC androgen receptor degrader in metastatic castration-resistant prostate cancer.
Publication reporting clinical data for an orally bioavailable PROTAC estrogen receptor degrader in advanced breast cancer.
Process development publication describing establishment of a commercial manufacturing route for an orally bioavailable PROTAC estrogen receptor degrader.
A research award recognizing innovation in targeted protein degradation with a $25,000 monetary prize; applications open Nov 1, 2026 and close Dec 31, 2026.
Peer-reviewed publication reporting Phase I/II clinical data for a PROTAC androgen receptor degrader in metastatic castration-resistant prostate cancer.
Publication reporting clinical data for an orally bioavailable PROTAC estrogen receptor degrader in advanced breast cancer.
Process development publication describing establishment of a commercial manufacturing route for an orally bioavailable PROTAC estrogen receptor degrader.